Data cutoff was 14 May 2021. We were originally given guidance of final AIPAC overall survival mid 2021. Why the hell was it pushed off for this conference? First I’d like to know how data 6 months old is given a late breaking designation at SITC? Second I’d like to know how the hell you execute that capital raise and hold this material information from the rest of the market? Was this a strategy to pull off that ridiculous 2 tranche capital raise?
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-2
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.5¢ | $547.1K | 1.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72820 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 49499 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |